In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

International Journal of Cancer

Volumn 102, Issue 5, 2002, Pages 463-468

  McClue, Steven J ^a   Blake, David ^a   Clarke, Rosemary ^a   Cowan, Angela ^a   Cummings, Lorna ^a   Fischer, Peter M ^a   MacKenzie, Mairi ^a   Melville, Jean ^a   Stewart, Kevin ^a   Wang, Shudong ^a   Zhelev, Nikolai ^a   Zheleva, Daniella ^a   Lane, David P ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

Anti tumour efficacy; Cell cycle; CYC202; Cyclin dependent kinase inhibitors; Roscovitine

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; ROSCOVITINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COMPARTMENTALIZATION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENCY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PURINES; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037058678     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10738     Document Type: Article

References (27)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Grana X, Reddy EP. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
3. Tsihlias J, Kapusta LM, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-23.
4. Chen YNP, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Blair KW, Kaelin WG Jr. Selective killing of transformed cells by cyclin/cyclin dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96:4325-9.
5. Meyer CA, Jacobs HW, Datar SA, Du W, Edgar BA, Lehner CF. Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression. EMBO J 2000;19:4533-42.
6. Morgan DO. Principals of CDK regulation. Nature 1995;374:131-4.
7. Feaver WJ, Svejstrup JQ, Henry NL, Kornberg RD. Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH/TFIIK. Cell 1994;79:1103-9.
8. Lu H, Fisher RP, Bailey P, Levine AJ. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol 1997;17:5923-34.
9. Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S, Meijer L. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-86.
10. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997;40:408-12.
11. Wang S, McClue SJ, Ferguson JR, Hull JD, Stokes S, Parson S, Westwood R, Fischer PM. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron Asymmetry 2001;12:2891-4.
12. Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, Bergonioux C, Brunn G, Buquet-Fageot C, Fagot D, Glab N, Goudeau H, et al. Cellular effects of Olomoucine, an inhibitor of cyclin dependent kinases. Biol Cell 1995;83:105-20.
13. Yakisich JS, Siden A, Vargas VI, Eneroth P, Cruz M. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine. Biochem Biophys Res Commun 1998;243:674-7.
14. Workman P, Balamin A, Hickman JA, McNally NJ, Mitchison NA, Pierrepoint CG, Raymond R, Rowlat C, Stevens TC, Wallace J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCR) guidelines for the welfare of animals in experimental neoplasia, second ed. UKCCR. Br J Cancer 1997;77:1-10.
15. Soussi T, Dehouche K, Béroud C. p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Hum Mutat 2000;15:105-13.
16. Meijer L, Borgne A, Mulner O, Chong JPJ, Blow J, Inagaki N, Inagaki M, Delcros J-G, Moulinoux J-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36.
17. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim S-H. Inhibition of cyclin dependent kinases by purine analogs: Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997;243:518-26.
18. Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg Med. Chem 1999;7:1281-93.
19. Mgbonyebi OP, Russo J, Russo IH. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Res 1998;18:751-6.
20. Mgbonyebi OP, Russo J, Russo IH. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 1999;15:1903-10.
21. Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 2000;19:3059-68.
22. van Engeland M, Kuijpers HJ, Ramaekers FC, Reutelingsperger CP, Schutte B. Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 1997;235:421-30.
23. Meijer L, Kim SH. Chemical inhibitors of cyclin-dependent kinases. In: Methods in Enzymology, vol. 283. New York, NY: Academic Press, 1997. 113-27.
24. Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 1997;236:4-15.
25. Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala LA, Scovassi AI, Meijer L, Prosperi E. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res 1998;245:8-18.
26. David-Pfeuty T. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 1999;18:7409-22.
27. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168-81.